StockData

Gossamer Bio vs Roivant Sciences

GOSS and ROIV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GOSS and ROIV compare

Roivant Sciences is the larger company, worth 5.2 times as much as Gossamer Bio ($28.0B against $5.4B).

Gossamer Bio grew revenue faster over the last twelve months (32.4% versus −67.6% for Roivant Sciences).

Gossamer Bio keeps more of each dollar of sales as profit, with a net margin of −235% compared with −3535% at Roivant Sciences.

Roivant Sciences scores higher on the StockData Score (7 against 1 for Gossamer Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGOSSROIV
Size and price
Market cap$5.4B$28.0B
Share price$11.04$38.71
Change, 1 year−94.9%90.8%
Change, 5 years−98.7%453%
Beta (5Y)2.330.42
Employees161721
StockData Score
Total score17 (better)
Valuation score00
Growth score1 (better)0
Performance score01 (better)
Health score06 (better)
Dividend score00
Valuation
P/S101× (better)3712×
P/B–6.6×
FCF yield−3.0%−2.9% (better)
Growth
Revenue growth (TTM)32.4% (better)−67.6%
Revenue growth, 5Y average–−19.1%
Profitability
Operating margin−312% (better)−7915%
Net margin−235% (better)−3535%
FCF margin−305% (better)−10901%
Return on equity–−6.2%
Return on invested capital–−407%
Financial health
Debt / equity–0.00
Interest coverage−15.2×–
Current ratio0.5316.72 (better)
Altman Z-score−15.2644.02 (better)
Piotroski F-score12 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions0.98%78.1%
Held by insiders2.8%13.9%
Insider net buying, 12 months–−$798M
Superinvestors holding11
Short interest, % of float0.28%7.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.